Thousands of people have been killed because of Ebola, since the plague outbreak in west Africa last year.To stop this situation, Beijing TianGuangshi biological technology co., LTD.and academy of military medical sciences created an antibody drug named MIL77. They used only three months to complete the development, pilot enlarge production and antibody detection of relevant state agencies which created a Chinese speed to develop emergency drug.

    This is the first time that Chinese domestic antibody drug went abroad, and successfully applied in western developed countries. In early 2015, MIL77 successfully cure 1 patient who was confirmed with Ebola virus infection in London,At present, the world health organization (who), Canada, Britain, and Medecins Sans Frontiers(MSF) have proposed to reserve MIL77 antibody drug.

    In the research and development of emergency antibody drug MIL77, Applikon also played an important role to accelerate the "Chinese speed".

Li Feng, general manager of Beijing TianGuangshi biological technology co., LTD.,is guiding his team to optimize cultivation process using Applikon BioBench 30L bioreactor.

Li Feng ‘s team are adjusted the culture conditions of Applikon BioBundle 3L bioreactor.